Methods for treatment of diseases

2:

• The unit dose formulation of claim 1, which comprises at least 600 mg of the superoxide dismutase mimetic.

3:

• The unit dose formulation of claim 1, wherein the superoxide dismutase mimetic is in the form of a lyophilized powder.

4:

• The unit dose formulation of claim 1, wherein the container further includes a pharmaceutically acceptable carrier.

5:

• The unit dose formulation of claim 4, wherein the pharmaceutically acceptable carrier comprises a buffered saline solution.

6:

• The unit dose formulation of claim 4, wherein the pharmaceutically acceptable carrier comprises a bicarbonate-buffered saline solution.

7:

• The unit dose formulation of claim 1, wherein X and Y are independently selected from monodentate ligands.

8:

• The unit dose formulation of claim 1, wherein X and Y are independently selected from the group consisting of aquo ligands, halo ligands, carboxylato ligands, and bicarbonato ligands.

9:

• The unit dose formulation of claim 8, wherein X and Y are chloro ligands.

10:

• The unit dose formulation of claim 1, wherein the formulation is stored in a container for storage or for administration to a patient.

11:

• The unit dose formulation of claim 10, wherein the container is a vial, a syringe, or an IV bag or bottle.

12:

• A method of treating a disease or condition in a human patient, the method comprising administering to the patient at least 25 mg of a superoxide dismutase mimetic at a rate of at least 100 mg/hr, wherein the superoxide dismutase mimetic corresponds to Formula (GC4419):
• and X and Y are independently neutral or negatively-charged ligands.

13:

• The method of claim 12, wherein the superoxide dismutase mimetic is administered at a rate of at least 600 mg/hr.

14:

• The method of claim 12, wherein at least 50 mg of the superoxide dismutase mimetic is administered to the patient.

15:

• The method of claim 12, wherein at least 600 mg of the superoxide dismutase mimetic is administered to the patient.

16:

• The method of claim 12, wherein the administration occurs within a 15 minute time period.

17:

• The method of claim 12, wherein the administration occurs within a 60 minute time period.

18:

• The method of claim 12, wherein the superoxide dismutase mimetic is administered parenterally.

19:

• The method of claim 12, wherein the superoxide dismutase mimetic is administered intravenously.

20:

• The method of claim 12, wherein the superoxide dismutase mimetic is administered as a pharmaceutical composition comprising the superoxide dismutase mimetic corresponding to Formula (GC4419) and a pharmaceutically acceptable carrier.

21:

• The method of claim 12, wherein the superoxide dismutase mimetic is administered in the form of the unit dose formulation of claim 1.

22:

• The method of claim 12, wherein the superoxide dismutase mimetic is dissolved in a solution comprising about 0.25 mg/mL to about 3.5 mg/mL superoxide dismutase mimetic and contained in an IV bag.

23:

• The method of claim 12, wherein X and Y are independently selected from monodentate ligands.

24:

• The method of claim 12, wherein X and Y are independently selected from the group consisting of aquo ligands, halo ligands, carboxylato ligands, and bicarbonato ligands.

25:

• The method of claim 24, wherein X and Y are chloro ligands.

26:

• A method of treating a disease or condition in a human patient, the method comprising administering to the patient a superoxide dismutase mimetic to provide an exposure as measured by an area under the curve (AUC) of at least 4,000 ng-h/mL as calculated from the measurement of the superoxide dismutase mimetic concentration in the patient's plasma, wherein the superoxide dismutase mimetic corresponds to Formula (GC4419):
• and X and Y are independently neutral or negatively-charged ligands.

27:

• The method of claim 26, wherein the administration provides an exposure as measured by an area under the curve (AUC) of at least 50,000 ng-h/mL as calculated from the measurement of the superoxide dismutase mimetic concentration in the patient's plasma.

28:

• The method of claim 26, wherein the superoxide dismutase mimetic is administered parenterally.

29:

• The method of claim 26, wherein the superoxide dismutase mimetic is administered intravenously.

30:

• The method of claim 26, wherein the superoxide dismutase mimetic is administered as a pharmaceutical composition comprising the superoxide dismutase mimetic corresponding to Formula (GC4419) and a pharmaceutically acceptable carrier.

31:

• The method of claim 26, wherein the superoxide dismutase mimetic is administered in the form of the unit dose formulation of claim 1.

32:

• The method of claim 26, wherein the superoxide dismutase mimetic is dissolved in a solution comprising about 0.25 mg/mL to about 3.5 mg/mL superoxide dismutase mimetic and contained in an IV bag.

33:

• The method of claim 26, wherein X and Y are independently selected from monodentate ligands.

34:

• The method of claim 26, wherein X and Y are independently selected from the group consisting of aquo ligands, halo ligands, carboxylato ligands, and bicarbonato ligands.

35:

• The method of claim 34, wherein X and Y are chloro ligands.

36:

• An article of manufacture, comprising packaging material and contained within said packaging material a parenteral formulation for treating a disease or condition or for protecting tissue against damage resulting from exposure to a cancer treatment in a patient in need thereof, wherein said parenteral formulation comprises a unit dose formulation of any of claims 1-20 and wherein said packaging material comprises a label or package insert with instructions for parenterally administering the dose to the patient.

37:

• The article of manufacture of claim 36, wherein the parenteral formulation is in solution form, comprising about 20 mg/mL superoxide dismutase mimetic, the formulation being a unit dose in a container.

38:

• The article of manufacture of claim 36, wherein the parenteral formulation is in solution form, comprising about 5 mg/mL superoxide dismutase mimetic, the formulation being a unit dose in a container.

39:

• The method of claim 36, wherein X and Y are independently selected from monodentate ligands.

40:

• The method of claim 36, wherein X and Y are independently selected from the group consisting of aquo ligands, halo ligands, carboxylato ligands, and bicarbonato ligands.

41:

• The method of claim 40, wherein X and Y are chloro ligands.